RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Satsuma Pharmaceuticals - Stock

Satsuma Pharmaceuticals Stocks 2024

Satsuma Pharmaceuticals Stocks

32.02 M

Ticker

STSA

ISIN

US80405P1075

WKN

A2PQPD

In 2024, Satsuma Pharmaceuticals had 32.02 M outstanding stocks, a 0% change from the 32.02 M stocks in the previous year.

The Satsuma Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e32.02
2028e32.02
2027e32.02
2026e32.02
2025e32.02
2024e32.02
2023e32.02
202232.02
202129.17
202017.41
201917.38
201816.09
201716.09

Satsuma Pharmaceuticals shares outstanding

The number of shares was Satsuma Pharmaceuticals in 2023 — This indicates how many shares 32.025 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Satsuma Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Satsuma Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Satsuma Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Satsuma Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Satsuma Pharmaceuticals Aktienanalyse

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals Inc is a young company that was founded in 2016. The company is a biotechnology company specializing in the development and commercialization of medications for the treatment of migraines. Its headquarters are located in South San Francisco, California. The business model of Satsuma Pharmaceuticals is based on the development of medications for the treatment of migraines. The company uses the latest research findings to develop more effective treatment options for patients with migraines. Migraine is one of the most common neurological disorders worldwide. It is estimated that approximately 1 billion people worldwide suffer from this disease, with women being more commonly affected than men due to hormonal differences. Satsuma Pharmaceuticals aims to combat this widespread disease by reducing the severity and frequency of migraine attacks for patients. To achieve its goals, Satsuma Pharmaceuticals has developed a technology platform that enables the development of new medications for the treatment of migraines. This platform is based on the latest developments in medication development and includes various areas such as drug research, preclinical development, clinical development, and approval processes. Satsuma Pharmaceuticals closely collaborates with leading physicians and researchers to develop its medications. The company conducts clinical trials to evaluate the effectiveness and safety of its medications and hopes to soon bring its first products to the market. Currently, Satsuma Pharmaceuticals is focused on the clinical development of a medication called STS101 for the treatment of migraines. This medication is a combination of an already established migraine medication and a new formulation technology. STS101 aims to quickly and effectively treat migraine attacks, thus improving the quality of life for patients with migraines. The company believes that STS101 represents a significant breakthrough in the treatment of migraines. Overall, Satsuma Pharmaceuticals is a promising company that has focused on combating one of the most common neurological disorders in the world. Through close collaboration with leading researchers and physicians, as well as new technology platforms, the company has the potential to make significant advancements in the development of medications for the treatment of migraines and thus improve the lives of millions of people worldwide. Satsuma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Satsuma Pharmaceuticals's Shares Outstanding

Satsuma Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Satsuma Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Satsuma Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Satsuma Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Satsuma Pharmaceuticals Stock

How many stocks are there of Satsuma Pharmaceuticals?

The current number of stocks of Satsuma Pharmaceuticals is 32.02 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Satsuma Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Satsuma Pharmaceuticals evolved in recent years?

The number of shares of Satsuma Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Satsuma Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Satsuma Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Satsuma Pharmaceuticals pay?

Over the past 12 months, Satsuma Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Satsuma Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Satsuma Pharmaceuticals?

The current dividend yield of Satsuma Pharmaceuticals is .

When does Satsuma Pharmaceuticals pay dividends?

Satsuma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, December, March, April.

How secure is the dividend of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Satsuma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Satsuma Pharmaceuticals located?

Satsuma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Satsuma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Satsuma Pharmaceuticals from 4/15/2014 amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on 3/28/2014.

When did Satsuma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/15/2014.

What was the dividend of Satsuma Pharmaceuticals in the year 2023?

In the year 2023, Satsuma Pharmaceuticals distributed 0 USD as dividends.

In which currency does Satsuma Pharmaceuticals pay out the dividend?

The dividends of Satsuma Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Satsuma Pharmaceuticals

Our stock analysis for Satsuma Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Satsuma Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.